- Home
- NMAI vs PRTA Comparison
NMAI vs PRTA Comparison
Compare NMAI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | PRTA |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.6M | 482.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NMAI | PRTA |
|---|---|---|
| Price | $12.88 | $9.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 109.7K | ★ 383.0K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.21 | $4.32 |
| 52 Week High | $13.96 | $14.60 |
Technical Indicators
Market Signals| Indicator | NMAI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 60.48 |
| Support Level | $12.72 | $9.54 |
| Resistance Level | $13.35 | $10.72 |
| Average True Range (ATR) | 0.18 | 0.55 |
| MACD | -0.10 | 0.11 |
| Stochastic Oscillator | 13.63 | 85.94 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.